| Literature DB >> 32822584 |
Frederic D Bushman1, Maire Conrad2, Yue Ren3, Chunyu Zhao4, Christopher Gu5, Christopher Petucci6, Min-Soo Kim6, Arwa Abbas7, Kevin J Downes8, Nina Devas4, Lisa M Mattei4, Jessica Breton2, Judith Kelsen2, Sarah Marakos4, Alissa Galgano4, Kelly Kachelries4, Jessi Erlichman4, Jessica L Hart9, Michael Moraskie4, Dorothy Kim4, Huanjia Zhang4, Casey E Hofstaedter4, Gary D Wu10, James D Lewis10, Joseph P Zackular7, Hongzhe Li3, Kyle Bittinger4, Robert Baldassano2.
Abstract
Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infection with Clostridioides difficile (CDI). IBD and IBD + CDI have overlapping symptoms but respond to distinctive treatments, highlighting the need for diagnostic biomarkers. Here, we studied pediatric patients with IBD and IBD + CDI, comparing longitudinal data on the gut microbiome, metabolome, and other measures. The microbiome is dysbiotic and heterogeneous in both disease states, but the metabolome reveals disease-specific patterns. The IBD group shows increased concentrations of markers of inflammation and tissue damage compared with healthy controls, and metabolic changes associate with susceptibility to CDI. In IBD + CDI, we detect both metabolites associated with inflammation/tissue damage and fermentation products produced by C. difficile. The most discriminating metabolite found is isocaproyltaurine, a covalent conjugate of a distinctive C. difficile fermentation product (isocaproate) and an amino acid associated with tissue damage (taurine), which may be useful as a joint marker of the two disease processes.Entities:
Keywords: Clostridioides difficile; Gram-positive; inflammatory bowel disease; isocaproate; isocaproyltaurine; metabolome; microbiome; taurine
Mesh:
Substances:
Year: 2020 PMID: 32822584 PMCID: PMC9332131 DOI: 10.1016/j.chom.2020.07.020
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 31.316